INO Description — Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals is a biotechnology company focused on bringing the designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus. Co.'s DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies, all of which utilize the two components of Co.'s integrated platform, SynCon® and CELLECTRA®. Co. is evaluating the feasibility of, conducting or planning clinical studies of its DNA medicines.
|
|
Free INO Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Buy (2.80 out of 4) 17th percentile
(ranked lower than approx. 83% of all stocks covered)
Analysts Forecast: INO Price Target Based on data provided by Zacks Investment Research via Quandl.com |
|